Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-558.24%
operating margin TTM
-575.42%
revenue TTM
151.23 Million
revenue per share TTM
0.69$
valuation ratios | |
|---|---|
| pe ratio | -7.03 |
| peg ratio | 0.30 |
| price to book ratio | 3.51 |
| price to sales ratio | 38.35 |
| enterprise value multiple | -9.17 |
| price fair value | 3.51 |
profitability ratios | |
|---|---|
| gross profit margin | 87.24% |
| operating profit margin | -575.42% |
| pretax profit margin | -558.24% |
| net profit margin | -558.24% |
| return on assets | -39.66% |
| return on equity | -64.55% |
| return on capital employed | -43.72% |
liquidity ratios | |
|---|---|
| current ratio | 14.81 |
| quick ratio | 14.73 |
| cash ratio | 13.98 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 205.39 |
| operating cycle | 376.16 |
| days of payables outstanding | 441.12 |
| cash conversion cycle | -64.96 |
| receivables turnover | 2.14 |
| payables turnover | 0.83 |
| inventory turnover | 1.78 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.11 |
| debt equity ratio | 0.14 |
| long term debt to capitalization | 0.11 |
| total debt to capitalization | 0.12 |
| interest coverage | -25.75 |
| cash flow to debt ratio | -2.85 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.08 |
| cash per share | 2.98 |
| operating cash flow per share | -1.01 |
| free cash flow operating cash flow ratio | 1.07 |
| cash flow coverage ratios | -2.85 |
| short term coverage ratios | -71.36 |
| capital expenditure coverage ratio | -15.35 |
Frequently Asked Questions
When was the last time Ocular Therapeutix, Inc. (NASDAQ:OCUL) reported earnings?
Ocular Therapeutix, Inc. (OCUL) published its most recent earnings results on 05-05-2026.
What is Ocular Therapeutix, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Ocular Therapeutix, Inc. (NASDAQ:OCUL)'s trailing twelve months ROE is -64.55%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Ocular Therapeutix, Inc. (OCUL) currently has a ROA of -39.66%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did OCUL's net profit margin stand at?
OCUL reported a profit margin of -558.24% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is OCUL's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 14.81 in the most recent quarter. The quick ratio stood at 14.73, with a Debt/Eq ratio of 0.14.